NICE approves lung cancer combination drug therapy for NHS use
People treated with pembrolizumab lived for 17.1 months on average versus 11.6 months for chemotherapy, trial data showed.
UK
Latest in
UK
UK MHRA grants approval to Pfizer’s oral antiviral for Covid-19
In a trial, Paxlovid, given within three days of symptom onset, lowered hospitalisation and death risk within 28 days by…
By
UK life sciences trade group calls for oral Covid-19 antiviral investment
The UK government must invest in Covid-19 antiviral treatments like it did with vaccines, said the chair of the UK…
By
A cloudy day in paradise for pharma tax havens in Cayman Islands & Bermuda?
A recent international agreement to harmonize tax rates evokes mixed views on the extent of the real-world impact for pharma…
By
Novartis to acquire UK’s Gyroscope Therapeutics for up to $1.5bn
With the acquisition, Novartis will gain rights to Gyroscope’s experimental gene therapy, GT005.
Molnupiravir Q4 forecast sales grow by 17,500% compared to Q3 forecast
Merck’s molnupiravir oral antiviral for Covid-19 is expected to generate $14.7bn in sales over the next four years.
By
UK’s MHRA grants authorisation for GSK-Vir Biotechnology’s Covid-19 drug
MHRA has recommended the use of GSK and Vir Biotechnology’s Xevudy within five days from the start of Covid-19 symptoms.
Middle-income countries’ healthcare sectors to keep rising through to 2024
Healthcare provision markets of middle-income countries are set to climb at an average annual rate of 5.7% in the next…
By